EVOEvotec SE
$1.52-62% 1Y
$1.52
$1.3452 weeks$4.15
Is the price fair?
What EVO's price assumes
Evotec SE did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.19× revenue.
1.19
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.27
Price / book · as of 2026-Q1
- EV / sales
- 1.19
EV / sales
Details›
- Price / bookas of 2026-Q1
- 1.27
- EV / EBIToperating margin −7.1%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 1.19
- Market capitalisation355.6 million shares, counted Dec 31, 2025
- $539M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #23 of 39 by RyuScore